According to our pooled analysis, ORRs of HBV+ HCC patients treated with anti-PD-1/PD-L1 immunotherapy were comparable to those of HBV− ones, whereas DCRs of HBV+ patients were significantly lower. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.